We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




First Cancer Patients Treated in Latin America Using Advanced Radiotherapy Technology

By HospiMedica International staff writers
Posted on 22 Jan 2010
Four patients with head and neck, rectal, and recurring prostate cancer are first in Latin America to benefit from new technology for fast delivery of image-guided intensity-modulated radiotherapy (IMRT), which potentially enables doctors to improve outcomes while extending modern care to more patients. More...


Physicians from Hope International Centro de Radioterapia of Guatemala (Guatemala City) are now treating four patients using RapidArc radiotherapy technology developed by Varian Medical Systems, Inc. (Palo Alto, CA, USA), one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

Clinicians at the center, which treats patients from across Central America, performed the first treatment for a 66-year-old attorney whose prostate cancer recurred a year after it was first treated using robotic surgery. His first RapidArc treatment was delivered in 3.16 minutes using two arcs, or rotations, of the machine around the patient. By comparison, conventional IMRT treatments would have taken eight to ten minutes.

Using the image-guidance technology that is integral to the RapidArc treatment process, clinicians were able to detect a 2 mm - 3 mm displacement of the targeted tumor after they positioned the patient for his first treatment. "We could then make a very fine adjustment in the patient's position, to ensure that we were accurately targeting the tumor and sparing surrounding tissues to the greatest extent possible,” said Luis A. Linares, M.D., medical director.

Dr. Linares and his medical team generated traditional IMRT treatment plans as well as RapidArc plans for all four patients, in order to compare and choose the one most likely to result in the best possible outcome. "In every case, the RapidArc plans were superior, as far as quality of the dose distribution was concerned,” Dr. Linares said. "We saw better coverage of the targeted tumor, and better normal tissue-sparing. For the rectal cancer patient, doses to the bladder and femoral heads were significantly lower with the RapidArc plan. For the prostate cancer patient, RapidArc did a better job of protecting both the bladder and the rectum. And for the patient with recurrent glioblastoma, we saw a definite advantage to the RapidArc plan, in terms of protecting the optic nerve and optic chiasm.”

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver advanced image-guided IMRT up to eight times faster than is possible with conventional IMRT. RapidArc technology directs the treatment beam at a tumor while continuously rotating around the patient. Traditional IMRT treatments are slower because they target tumors using a complex sequence of fixed beams from multiple angles. "Faster treatments have the potential to be even more precise, since there is less chance of the patient or tumor moving during treatment,” Dr. Linares said.

"We are pleased to hear that the first RapidArc treatments have now been delivered at this important cancer treatment facility in Central America,” said James Miles, Varian's director of operations for Latin American and the Caribbean. "RapidArc is enabling more and more cancer centers around the world to offer patients the most modern treatments available.”

Previous studies have demonstrated improved outcomes for prostate and head and neck cancer patients treated with IMRT as compared with other forms of radiotherapy, and revealed the magnitude of tumor motion that can take place during a prostate cancer treatment.

Related Links:
Hope International Centro de Radioterapia of Guatemala
Varian Medical Systems



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
PACS Workstation
PaxeraView PRO
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.